Danaher Corporation $DHR Shares Bought by Osterweis Capital Management Inc.

Key Points

• Osterweis Capital Management Inc. increased its holdings in Danaher Corporation by 26% during the first quarter, now owning over 128,000 shares valued at approximately $26.35 million.
• Danaher reported earnings per share of $1.80 for the last quarter, exceeding estimates, with a revenue of $5.94 billion, up 3.4% year-over-year.
• The company declared a quarterly dividend of $0.32 per share, representing an annualized yield of 0.7%, with the payment scheduled for October 31st.

Osterweis Capital Management Inc. boosted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 26.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,535 shares of the conglomerate's stock after buying an additional 26,494 shares during the period. Osterweis Capital Management Inc.'s holdings in Danaher were worth $26,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp increased its position in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DHR. Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Finally, Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Stock Up 1.4%

Danaher stock opened at $195.23 on Friday. The firm has a market cap of $139.79 billion, a price-to-earnings ratio of 41.54, a price-to-earnings-growth ratio of 2.69 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The business's 50-day moving average price is $201.47 and its 200 day moving average price is $199.04. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.